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Summary 22 
 23 
Enhancers are cis- regulatory genetic elements crucial for controlling temporal and 24 
cell-type specific patterns of gene expression. Active enhancers generate bi-25 
directional non-coding RNA transcripts called enhancer RNAs (eRNAs). eRNAs are 26 
important for stimulating gene expression, but precise mechanisms for this ability 27 
remain unclear. Here we highlight recent findings that demonstrate a direct 28 
interaction between RNAs and the transcriptional co-activator Creb-binding protein 29 
(CBP). Notably, RNA binding could stimulate the core histone acetyltransferase 30 
activity of the enzyme, observable in cells as a link between eRNA production, CBP-31 
dependent histone acetylation and expression of genes regulated by specific 32 
enhancers. Although RNA binding was independent of RNA sequence, specificity 33 
arises in a locus-specific manner at transcribed sites where CBP was bound to 34 
chromatin. The results suggest a functional role for eRNAs as regulatory molecules 35 
that are able to stimulate the activity of a key epigenetic regulatory enzyme, thereby 36 
promoting gene expression. Furthermore, they suggest an intriguing role for eRNAs: 37 
by modulating the activity of chromatin modifying enzymes, they could directly impact 38 
transcription by altering the chromatin environment. 39 
 40 
 41 
  42 
 2 
Introduction 43 
 44 
The transcription of bi-directional, non-coding RNAs known as enhancer RNAs 45 
(eRNAs) is a key signature of active enhancer regions1. It is now widely recognized 46 
that eRNA transcripts themselves play direct roles in promoting enhancer dependent 47 
gene expression; depletion of eRNAs can therefore affect transcription from 48 
enhancer-associated genes 2-7. eRNAs have been implicated in controlling looping 49 
between enhancers and promoters 5,8. In human breast cancer cells, eRNAs stabilize 50 
interactions between estrogen-receptor activated enhancers and promoters by 51 
interacting directly with cohesin 5. eRNAs also facilitate recruitment of Mediator to 52 
promoters 4 and promote the release of paused RNA Polymerase II (Pol II) from the 53 
promoter into the gene body at poised genes 9. However, until recently eRNAs were 54 
not thought to play a direct role in directing the post-translational modification of 55 
histones to modify the chromatin environment. Indeed, enhancer specific histone 56 
methylation changes that signpost enhancer activity, such as di-methylation of 57 
histone H3 on lysine 4 (H3K4me2), arise due to transcription of the active enhancer 58 
by RNA polymerase II; these modifications are independent of eRNA transcripts 10. 59 
As H3K4me2 occurs at enhancers without the need for eRNAs, this raises the 60 
question of whether eRNAs are capable of sculpting the chromatin milieu.  61 
The transcriptional co-activator Creb binding protein (CBP) contains a core 62 
enzymatic histone acetyltransferase (HAT) activity within a central catalytic domain 63 
11,12. CBP acts as a transcriptional Ônetwork-hubÕ, interacting with hundreds of 64 
transcription factor (TF) binding partners 13. Enhancers are typically formed of 65 
clusters of TF binding sites; consequently, CBP is recruited to almost all enhancers 66 
through its interactions with TFs, and CBP occupancy is considered a defining 67 
characteristic of enhancer elements 14,15. Localizing CBP HAT activity to enhancers 68 
using de-activated Cas9 nuclease (dCas9) is sufficient to promote transcription of 69 
enhancer-associated genes 16. Moreover, CBP-dependent histone acetylation, 70 
specifically acetylation of histone H3 on lysine 27 (H3K27ac), is a characteristic 71 
epigenetic signature of enhancers across the genome 14,17.  72 
 73 
A number of recent studies have revealed that chromatin associated proteins interact 74 
with RNA in cells at high frequency 18-20. In many cases, these interactions do not 75 
involve canonical or previously annotated RNA binding regions (RBRs) within the 76 
interacting proteins 18,19. Notably, RNA binding through non-canonical regions 77 
appears to be especially common for chromatin-modifying epigenetic enzymes 18. 78 
Chromatin-associated enzymes or enzyme complexes that bind to RNA, such as 79 
PRC2 and DNMT1, demonstrate a slight preference for structured RNA elements, 80 
but binding is often considered to be promiscuous as they have similar affinities for 81 
more than one RNA sequence 21-25. Moreover, a number of examples have now been 82 
described where RNA binding can directly modulate the catalytic activity of these 83 
enzymes 21,22,25-28. 84 
 85 
We recently demonstrated an interaction between CBP and RNA 29, where specificity 86 
for RNA binding arises in a locus-specific manner, dictated by locations of CBP 87 
 3 
recruitment to chromatin. Although independent of RNA sequence, these interactions 88 
were sufficient to stimulate the catalytic HAT activity of the CBP enzyme, increasing 89 
CBP-dependent H3K27ac and thus promoting transcription 29. Given the high 90 
frequency of interactions between RNAs and chromatin associated proteins, this 91 
raises an intriguing question: Does RNA binding convey a localized activity profile to 92 
chromatin bound epigenetic enzymes, and does this enable eRNAs to modify the 93 
local chromatin environment at a particular locus? Here, we utilize the example of 94 
CBP to explore the potential role of eRNAs as regulators of chromatin-modifying 95 
enzyme activity, and explore the implications of such a mechanism for enhancer 96 
function. 97 
 98 
 99 
Locus specificity for RNA binding 100 
 101 
Our data revealed that CBP could interact with RNA in cells under native conditions, 102 
and importantly that CBP binds directly to RNA in photoactivatable ribonucleoside-103 
enhanced crosslinking and immunoprecipitation (PAR-CLIP) experiments 29-31. 104 
Profiling of CBP-bound RNAs across the genome using high-throughput sequencing 105 
of PAR-CLIP libraries, revealed that bound RNAs arise from sites where CBP is 106 
recruited to chromatin. As CBP is strongly bound to enhancer regions and promoters, 107 
we observed a strong bias towards RNAs transcribed from these regions. These 108 
transcripts were especially enriched given their relatively low abundance and high 109 
turnover compared to coding transcripts from exonic regions. CBP therefore 110 
preferentially binds to RNAs transcribed from sites where it is recruited to chromatin 111 
29. Thus, although binding does not rely on a particular RNA sequence, RNA binding 112 
to CBP displays locus-specificity Ð transcripts are preferentially bound according to 113 
where CBP is bound to chromatin (Figure 1A).  We note that, in common with other 114 
interactions between chromatin modifiers and RNA, a preference for specific RNA 115 
structures within eRNAs remains a possibility and requires further investigation for 116 
CBP. 117 
 118 
One important consequence of locus-specific binding, was that RNAs interacting with 119 
CBP in vivo included a large number of eRNAs due to the high frequency of CBP 120 
recruitment at enhancers. A locus-specific binding model is logical in the context of 121 
the biological function of CBP: CBP is almost universally recruited to enhancer 122 
elements across the genome, regions that differ in their underlying DNA sequence. 123 
eRNAs arising from these enhancers will therefore also display different sequences 124 
and structural features. By retaining the ability to interact with RNAs independent of 125 
sequence, the activity of CBP could thus be modulated by RNAs wherever it binds to 126 
chromatin, i.e by eRNAs transcribed from any enhancer element where CBP is 127 
bound. Locus-specificity therefore opens the possibility that RNA binding to CBP, 128 
and potentially other epigenetic enzymes, could confer highly localized effects on 129 
specific CBP populations across the genome. Thus, RNAs, and eRNAs in particular 130 
could function as local regulators of CBP activity.  131 
 132 
 133 
 4 
Direct binding to eRNAs stimulates CBP HAT activity 134 
 135 
To investigate this potential regulatory function of eRNAs in more detail, we 136 
reconstituted binding to CBP in vitro29. RNA pull downs and EMSAs revealed that 137 
eRNAs bind to the large, full-length CBP protein, but also to the much smaller 138 
catalytic HAT domain of CBP. We mapped RNA binding within the HAT domain to a 139 
contiguous region of 49 basic and disordered amino acids 11,12,29. Importantly, this 140 
RBR had been previously identified as an important regulatory motif for the HAT 141 
activity of CBP 32. This region, known as the activation loop, binds within the active 142 
site of CBP and blocks substrate binding until it is displaced by auto-acetylation 32. 143 
Consistent with the importance of the activation loop for regulating catalytic activity, 144 
we found that RNA binding to the RBR within the HAT domain caused a pronounced 145 
stimulation of the HAT activity of CBP (Figure 1B). This was evident both in 146 
radioactive filter binding HAT assays, and by western blot for specific CBP-147 
dependent histone modifications, H3K27ac and H4K5ac, on reconstituted 148 
nucleosomes in vitro. HAT assays under steady state conditions revealed that 149 
stimulation results from displacement of the activation loop from the active site upon 150 
RNA binding 29 (Figure 1B). Our results also revealed that eRNAs possess variable 151 
abilities to bind to CBP, and to stimulate its HAT activity. For example, eRNAs that 152 
failed to bind strongly to CBP in pull-down experiments, also failed to strongly 153 
upregulate its HAT activity, and different eRNA sequences produced different 154 
patterns of stimulation 29.  These findings support a model that various sequences, 155 
and potentially structures of eRNAs, may have differential binding to CBP and 156 
generate alternative patterns of HAT stimulation. 157 
 158 
Therefore, one intriguing possibility is that the activity of CBP can be modulated by 159 
eRNAs at different enhancers to generate a tailored activity profile at that enhancer 160 
(Figure 1C). Such a model could help to explain the observation that some eRNAs 161 
display strong strand-specificity in their ability to stimulate gene expression: if one 162 
strand is able to bind strongly to CBP and stimulate activity, but the other is unable to 163 
bind, then a difference in the ability of each eRNA strand to direct transcription would 164 
be observed at that enhancer (Figure 1D). We also note that while we observe a bias 165 
towards eRNA binding to CBP due to the prevalence of enhancer-bound CBP 33, 166 
promoter-derived transcripts could also potentially bind to and stimulate CBP activity 167 
(Figure 1C). The observation that eRNAs can control the activity of CBP in an 168 
enhancer specific manner, can also help explain the surprising observation that 169 
recruitment of CBP to enhancers and promoters is a relatively poor predictor of 170 
downstream gene activation 33. For example, eRNAs that strongly stimulate the 171 
activity of CBP could contribute to a stronger enhancer activity profile. However, 172 
more work is required to fully characterize the relationship between transcribed 173 
eRNAs, stimulation of CBP activity and enhancer strength. 174 
 175 
 176 
Could eRNA have a general role as a regulatory molecule? 177 
 178 
 5 
The regulatory activation loop within the HAT domain of CBP, which contains the 179 
RBR, binds in the active site of the enzyme and blocks substrate binding. The ability 180 
to bind within the CBP active site is derived from the positive charge of the RBR 181 
within the activation loop; this positive charge also enables the loop to bind to RNAs. 182 
Other histone acetyltransferases, such as the MYST family member Males Absent on 183 
the First (hMOF) are not regulated by an activation loop in the manner of CBP, thus 184 
their HAT activity remains unaffected by the presence of RNA 29.  185 
 186 
Nevertheless, it is clear that the activity of other epigenetic-enzyme complexes, such 187 
as PRC2 and DNMT1, are sensitive to RNA binding: Binding of RNA to PRC2 188 
decreases both its methyltransferase activity and recruitment to promoter regions 189 
22,25,26, and ncRNAs transcribed proximal to the C/EBPA locus interact with DNMT1 to 190 
block DNA methylation at the promoter 21. In both instances, RNA binding was driven 191 
more by RNA secondary structure than sequence, with more structured RNAs 192 
binding more strongly, and different RNA sequences producing different effects on 193 
enzyme activity 21-23. In cells, the ability of ncRNA to inhibit the methyltransferase 194 
activity of PRC2 is thought to arise from competition between RNA and nucleosomes 195 
for binding to PRC2 25. For DNMT1, RNA binding was mapped to the catalytic 196 
domain of the enzyme 21. This suggests that in order for a chromatin-modifying 197 
enzyme to be susceptible to direct regulation by RNA binding, there must be a link 198 
between potential RBRs within the protein and the catalytic domain. Interestingly, 199 
many epigenetic complexes - such as PRC2 - contain multiple subunits and 200 
components, often with individual abilities to bind to RNA. It remains to be 201 
determined what the combined effect of RNA binding to individual components of 202 
these complexes plays to regulate overall complex activity. Full elucidation of the 203 
mechanisms of RNA-dependent stimulation will require further biochemical and 204 
structural studies of the interactions between the enzyme and bound RNA species. 205 
 206 
 207 
Concluding remarks 208 
 209 
Recent studies have highlighted the high frequency of binding between chromatin-210 
associated proteins or enzyme complexes and RNA in cells, and the importance of 211 
non-canonical RBRs for these interactions 18,19. The observation that locus-specific 212 
RNA binding to CBP can directly stimulate its catalytic HAT activity presents an 213 
interesting role for these interactions: RNA binding events could enable local 214 
ÔtailoringÕ of enzymatic-activity profiles.  215 
 216 
In the case of CBP, this tailoring is driven by the binding of RNAs transcribed 217 
proximal to sites where CBP is recruited to chromatin. RNAs bind to CBP through a 218 
non-canonical, positively charged RBR within the catalytic HAT domain. Because this 219 
region is crucial for the regulation of CBP activity, RNA binding can stimulate the 220 
catalytic activity of the enzyme and promote gene expression. The structure of CBP, 221 
and its method of regulation by the activation loop, renders it particularly susceptible 222 
to regulation by RNA binding to this region. Whilst it is increasingly clear that RNA 223 
binding to other chromatin-modifying enzymes is widespread, the extent to which this 224 
 6 
binding can modulate their enzymatic activity is less well understood. A number of 225 
examples suggest that RNA does play such a regulatory role 21,22,25-28, however 226 
further biochemical work is required to fully determine the mechanisms that RNAs 227 
use to modulate the activity of these complexes.  228 
 229 
For CBP, locus-specific RNA binding leads to preferential binding of CBP to eRNAs, 230 
as CBP is enriched at enhancers. Our results suggest a functional role for eRNAs as 231 
regulatory molecules that are able to stimulate the activity of a key epigenetic 232 
regulatory enzymes, thereby promoting gene expression. Furthermore, they suggest 233 
an intriguing, RNA sequence-independent (but potentially structure-dependent) role 234 
for eRNAs in modulating the activity of chromatin modifying enzymes, that could 235 
directly impact transcription by altering the chromatin environment. In contrast, we 236 
note that enhancer-specific methylation changes appear to be reliant on transcription 237 
at enhancers, rather than eRNA transcripts themselves 10. A key outstanding 238 
question is whether eRNA transcripts can play a role in modifying the activity of 239 
epigenetic complexes when enhancers loop to contact promoter regions.  240 
 241 
Chromatin-modifying enzymes and enzyme complexes are crucial for directing gene 242 
expression profiles across the genome. In particular, eRNAs are attractive 243 
candidates as regulatory molecules due to their highly localized expression profiles, 244 
rapid turnover and low abundance 2,3,5. The prevalence of RNA binding to chromatin-245 
modifying enzymes, and the potential for modulation of their catalytic activity, 246 
suggests that RNAs could modulate their activity in a similar manner to CBP to 247 
generate tailored patterns of histone modifications and gene expression profiles.  248 
 249 
 250 
Figure Legend 251 
 252 
Figure 1: RNA binding can generate localized CBP activity profiles and tailored 253 
patterns of histone acetylation. A) Locus specificity for RNA binding to CBP. CBP 254 
bound RNAs (dashed-line) correspond to sites of CBP recruitment to chromatin 255 
(dark-grey) and nascent RNA transcription (light-grey) at enhancers and promoters; 256 
B) RNA binding to the activation loop of CBP stimulates catalytic HAT activity by 257 
displacing the loop from the active site, and thereby promotes CBP dependent 258 
histone acetylation (H3K27ac); C) eRNA binding could generate enhancer specific 259 
patterns of CBP activity by differential regulation of CBP activity. At more active 260 
enhancers, CBP activity is stimulated more strongly by eRNA binding (arrows) than 261 
at enhancers with weak stimulation of CBP activity (crosses); D) Differences in the 262 
ability of sense and antisense eRNA transcripts to stimulate CBP activity. The eRNA 263 
strand that binds and stimulates CBP strongly (arrows) could promote associated 264 
gene expression more strongly than weaker binding eRNA strands (crosses).  265 
 266 
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